SEMA4 HOLDINGS CORP. (NASDAQ: SMFR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Sema4 Corp. (NASDAQ: SMFR)
08 sept. 2022 14h00 HE
|
Bernstein Liebhard LLP
Did you lose money on investments in Sema4 Holdings? If so, please visit Sema4 Holdings Corp. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to...
SMFR Class Action Complaint Filed: Johnson Fistel, Globally-Recognized Law Firm Encourages Shareholders to Submit Their Sema4 Losses
08 sept. 2022 08h27 HE
|
Johnson Fistel, LLP
SAN DIEGO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Sema4 Holdings Corp....
Sema4 to Participate at Two Investor Conferences in June 2022
26 mai 2022 08h00 HE
|
Sema4
STAMFORD, Conn., May 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate...
Sema4 Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 mai 2022 16h05 HE
|
Sema4
STAMFORD, Conn., May 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that, effective as of May 2, 2022, the...
Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms
02 mai 2022 07h45 HE
|
Sema4
Acquisition creates an AI-driven advanced health intelligence company, now leveraging one of the largest genomic testing platforms in the U.S. Katherine Stueland, former President and CEO of GeneDx,...
Sema4 to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
26 avr. 2022 16h05 HE
|
Sema4
STAMFORD, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for...
Sema4 Achieves HITRUST CSF Certification
06 avr. 2022 08h00 HE
|
Sema4
STAMFORD, Conn., April 06, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that its health intelligence platform,...
Sema4 and Mount Sinai Use Integrative Network Analysis to Identify Potential New Lung Cancer Therapy
05 avr. 2022 08h00 HE
|
Sema4
STAMFORD, Conn., April 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an artificial intelligence (AI)-driven genomic and clinical data intelligence platform company, and researchers from the...
Sema4 and BioSymetrics Partner on Data-Driven Drug Discovery to Advance Precision Medicine
22 févr. 2022 08h00 HE
|
Sema4
STAMFORD, Conn. and BOSTON and TORONTO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, and BioSymetrics, a...
Sema4 to Participate at Two Upcoming Investor Conferences in February
03 févr. 2022 16h05 HE
|
Sema4
STAMFORD, Conn., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will...